Viyash Scientific Limited reported a strong performance for the first quarter of FY27 (ended June 30, 2026). Revenue from operations grew by 19.5% YoY to ₹9,464 million. EBITDA saw a substantial increase of 59.2% YoY, reaching ₹2,047 million, with an EBITDA margin of 21.6%. The company also highlighted the strategic acquisition of Bio For Life in Italy, aimed at strengthening its companion animal segment and expanding its European market presence.
Viyash Scientific Reports Robust Q1 FY27 Performance
Viyash Scientific Limited has announced its financial results for the first quarter of Fiscal Year 2027, ending June 30, 2026, showcasing significant year-on-year growth across key financial metrics. The company’s strategic focus on integration, robust execution, and market expansion has underpinned these strong results.
Key Financial Highlights (Q1 FY27)
The company reported a notable increase in its financial performance:
- Revenue from Operations: Increased by 19.5% year-on-year to ₹9,464 million.
- EBITDA: Saw a substantial growth of 59.2% year-on-year, reaching ₹2,047 million.
- EBITDA Margin: Improved to 21.6%, a notable increase of 530 basis points compared to the previous year.
- Net Debt to LTM EBITDA: Reduced to a healthy 0.1x.
Strategic Acquisition and Business Expansion
A significant strategic development highlighted in the presentation is the acquisition of Bio For Life in Italy. This acquisition is poised to bolster Viyash Scientific’s strategic focus on the companion animal segment. It is expected to provide enhanced market access in Italy and serve as a platform for launching its product portfolio in key European markets. The company views this as a crucial step in advancing its long-term growth strategy.
Operational Performance and Outlook
The Q1 FY27 performance reflects the continued success of the company’s integration efforts and the combined entity’s strength. Viyash Scientific emphasized its commitment to disciplined execution, operational efficiency, and strategic investments. The company is poised for sustainable growth, leveraging its integrated platform and expanding its global reach.
Business Segments Performance
The Revenue Distribution report for Q1 FY27 indicates strong performance across various segments:
- Formulations reported ₹5,547 million in Q1 FY27, a 33% increase year-on-year, driven by growth in Europe (13% YoY), Emerging Markets (36% YoY), India (63% YoY), and USA (60% YoY).
- APIs contributed ₹3,833 million in Q1 FY27, with a 4% year-on-year growth.
R&D and Manufacturing Capabilities
Viyash Scientific maintains a strong R&D landscape with dedicated centers for API, Human Health Formulations, and Animal Health Formulations. The company operates 16 world-class manufacturing facilities globally, including 10 API manufacturing sites, underscoring its integrated operational capabilities.
Source: BSE
